Biological cell preparation for treating knee joint injury and preparation method thereof
Through biological cell preparations of umbilical cord blood mesenchymal stem cells and hyaluronic acid, the problems of poor self-repair ability and major side effects in knee injury treatment are solved, meniscus regeneration and cartilage tissue repair are achieved, and joint function is significantly improved and security.
Patent Information
- Application Number
- CN202411146908.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-19
AI Technical Summary
The existing treatment methods for knee joint injury have problems such as poor self-repair ability, obvious side effects, and many post-operative complications, which are difficult to effectively solve the root causes of meniscus damage.
Using biological cell preparations that bind umbilical cord blood mesenchymal stem cells and hyaluronic acid, the growth factor secretion and immune regulation mechanism of stem cells promotes self-repair of meniscus and reconstruction of cartilage tissue, reducing joint pain and inflammatory responses.
It significantly promotes the regeneration of meniscus and the repair of cartilage tissue, reduces joint pain and inflammation, improves joint mobility, and reduces side effects, achieving effective treatment for knee joint injuries.
Smart Images

Figure BDA0005002450730000082 
Figure BDA0005002450730000091 
Figure BDA0005002450730000093
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of cell preparations, and in particular to a biological cell preparation for treating knee joint injuries and a preparation method thereof. Background Art
[0002] The main treatments for knee injuries are:
[0003] 1. Physical therapy: The symptoms of meniscus injury are mild and can be relieved by hot compresses, manual therapy, electrotherapy, etc. At the same time, the affected limb should be braked and a brace can be used for fixation if necessary.
[0004] 2. Drug treatment: For moderate meniscus injury accompanied by severe pain, non-steroidal anti-inflammatory analgesics such as ibuprofen and loxoprofen sodium can be taken. If necessary, hyaluronic acid can be injected into the joint cavity to protect the synovial membrane of the joint. Hyaluronic acid only serves as a lubricant and does not cure the root cause. If the patient has an allergic constitution, he may be allergic to the drug components in the sodium hyaluronate injection, which may cause allergic reactions such as local redness, itching, and rash after injection.
[0005] 3. Surgical treatment: Due to factors such as insufficient blood supply to the meniscus, the self-repair ability of the meniscus is poor, and the surgical effect is unsatisfactory. Meniscus surgery may cause damage to the muscles around the knee joint, and patients may experience limited knee joint movement after surgery. If the patient does not pay attention to postoperative care, it may cause wound infection, local pain, redness and swelling and other symptoms. If the patient does not pay attention to rest after surgery and gets up and moves too early, it may cause blood clots in the knee joint, causing local pain, swelling and other symptoms. If the patient does not pay attention to keeping warm after surgery, it may cause degenerative lesions in the knee joint, causing knee pain, swelling and other symptoms. Summary of the invention
[0006] The purpose of the present invention is to provide a biological cell preparation for treating knee joint injuries and a preparation method thereof, so as to solve the problems raised in the above-mentioned background technology.
[0007] In order to solve the above technical problems, the present invention provides the following technical solutions:
[0008] A biological cell preparation for treating knee joint injury and a preparation method thereof, wherein the specific preparation steps are as follows:
[0009] S1: Take the qualified umbilical cord blood and transfer it to a centrifuge tube for the first centrifugation, collect the upper plasma, and keep the lower liquid for later use; add calcium chloride dihydrate solution to the upper plasma to dilute it, invert and mix it, transfer it to a centrifuge tube, and place it in a water bath at 37°C for 40-50 minutes. After the plasma coagulates, break it and perform the second centrifugation, collect the upper clear liquid, freeze it at -80°C for 1-2 hours, thaw it in a water bath at 37°C, perform the third centrifugation, take the supernatant, and filter it through a 0.22μm filter to obtain serum;
[0010] S2: Take the lower layer of liquid reserved in S1 and supplement the phosphate buffer solution, slowly add it to the lymphocyte separation solution, centrifuge and separate the layers, and obtain the following from bottom to top: red blood cell layer, separation solution layer, buffy coat layer, PBS mixed solution layer; aspirate the cells in the buffy coat layer, resuspend them with physiological saline, wash them 3 times, resuspend them in the serum culture medium prepared in S1, and culture them on the wall to obtain umbilical cord blood mesenchymal stem cells;
[0011] S3: Add hyaluronic acid to deionized water, stir to dissolve, add carbodiimide and N-hydroxysuccinimide to dissolve, adjust the pH to 5-6, stir and react for 30 minutes in the dark, add L-cysteine hydrochloride to dissolve, adjust the pH to 5-6, stir and react for 5 hours in the dark; after the reaction, put into a dialysis bag, place in a hydrochloric acid solution with a pH of 5 and a hydrochloric acid solution with a pH of 5 containing 1 wt% sodium chloride, dialyze at 21°C in the dark for 4-6 days, take out and freeze-dry to obtain a freeze-dried sponge solid
[0012] S4: Take the freeze-dried sponge solid and add deionized water, stir to dissolve, add umbilical cord blood mesenchymal stem cells, serum, and sodium hyaluronate, mix, then add β-glycerophosphate disodium, dissolve and place in a 37°C water bath to obtain a biological cell preparation.
[0013] Among them, the first centrifugation parameter setting in S1 is: 700×g at 4°C, centrifugation for 10 minutes; the second centrifugation parameter setting is: 2000×g at 4°C, centrifugation for 5 minutes; the third centrifugation parameter setting is: 750×g at 4°C, centrifugation for 10 minutes.
[0014] The centrifugation parameters in S2 were set at 900 × g for 20 min at 25 °C.
[0015] The concentration of umbilical cord blood mesenchymal stem cells is (1~1.5)×10 7 / mL, and the concentration of sodium hyaluronate is 12mg / mL. Compared with the prior art, the beneficial effects achieved by the present invention are:
[0016] 1. Umbilical cord blood mesenchymal stem cells
[0017] (1) Stem cell therapy can secrete growth factors in the patient's body to activate the self-repair mechanism, home to the site of meniscus damage, promote meniscus regeneration, and solve the problem of wear and tear from the root.
[0018] (2) Once stem cells are injected into the patient's joints, they will secrete growth factors and cytokines according to the needs of cartilage, promote cell proliferation, differentiate into different cell types, and inhibit cartilage apoptosis.
[0019] (3) Stem cell therapy can secrete a variety of cytokines to participate in immune responses, such as chondrocytes, adipocytes, synovial cells and other tissue cells, while achieving homing, survival, and differentiation into chondrocytes in the body, promoting meniscus tissue reconstruction. Therefore, the application of stem cells in repairing bone and cartilage injuries has a high application value.
[0020] (4) Mesenchymal stem cells have immunomodulatory mechanisms, anti-inflammatory effects, and the ability to repair damaged tissues. They have immunosuppressive properties for meniscus damage repair. They have low immunogenicity and almost no side effects.
[0021] 2. Umbilical cord blood serum
[0022] The various cytokines in cord blood serum include platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), insulin-like growth factor (IGF), fibroblast growth factor (FGF), bone morphogenetic protein 2, 4, 6, and IL-1; they promote osteoblast proliferation, and synergistically stimulate cell proliferation and differentiation in the body to achieve tissue and organ repair and regeneration. Chondrocytes can proliferate under the promotion of these growth factors, inhibit the function of osteoclasts, and induce the synthesis of cartilage matrix, promoting the healing of cartilage and other tissues.
[0023] 3. Hyaluronic acid
[0024] (1) It increases joint lubrication and stimulates cell proliferation, thereby prolonging the residence time of stem cells.
[0025] (2) Covering the surface of articular cartilage, protecting the cartilage, inhibiting the deformation of articular cartilage, and inhibiting the precipitation of proteoglycans from the cartilage matrix.
[0026] (3) Protect joint tissue, inhibit pain, increase joint mobility, and improve joint contracture, which has an improving effect on joint function.
[0027] (4) It promotes the secretion of hyaluronic acid by synovial tissue, has an effect on pathological joint fluid, and promotes the biosynthesis of its own high-molecular-weight hyaluronic acid. DETAILED DESCRIPTION
[0028] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0029] In the experiment, human umbilical cord mesenchymal stem cell osteogenic, adipogenic and chondrogenic differentiation medium were purchased from Aibixin (Shanghai) Biotechnology Co., Ltd.
[0030] Umbilical cord blood was collected from healthy pregnant women at 39-40 weeks of normal delivery or cesarean section. The five virus tests (HIV, TP, HAV, HBV, HCV) of the pregnant women were all negative, and there was no history of infectious diseases. Under clean conditions in the operating room, the umbilical cord blood was collected after obtaining the informed consent of the pregnant woman. Serological tests for HBsAg, HCV antibodies, syphilis spirochete antibodies, HIV antibodies and cytomegalovirus IgM were all negative. The umbilical cord blood was collected under sterile conditions in an umbilical cord blood collection bag containing an anticoagulant. Principles for the selection of umbilical cord blood: The color of umbilical cord blood plasma is clear and light yellow, and it is transported to the laboratory at 4°C.
[0031] Example 1: Extraction of serum and detection and identification:
[0032] The umbilical cord blood that passed the test, had no hemolysis, no blood clots, and was sufficient was transferred to a 50 ml sterile centrifuge tube and centrifuged (centrifugation parameters: 4 ° C, 700 × g, 10 min), and the upper plasma was collected. 1 mol / L CaCl2·2H2O solution was added to the mixed plasma to make Ca 2+ The final concentration is 20mmol / L. Invert and mix, and transfer the liquid to a 250ml centrifuge tube; in a 37°C water bath for 40min, wait for the coagulation system to precipitate (plasma coagulation), break the jelly-like plasma block and centrifuge (centrifugation parameters: 4°C, 2000×g, 5min), the upper clear liquid is the required serum, and the lower milky yellow precipitate is fibrinogen. Collect the upper serum, freeze it at -80°C for 1h, thaw it in a 37°C water bath, and centrifuge it (centrifugation parameters: 750×g, 4°C, 10min), take the supernatant and filter it through a 0.22μm filter, and keep 5ml of sample for pathogenic microorganism detection (bacteria, fungi, mycoplasma, endotoxin); obtain serum.
[0033] 1) Serum quality testing:
[0034] ① Bacterial detection: There was no colony growth in both aerobic bacteria detection and anaerobic bacteria detection.
[0035] ②Mycoplasma detection: no colony growth.
[0036] ③Endotoxin test: The culture medium is clear and transparent without any change, and no mycoplasma grows. Endotoxin test result: There is gel in the positive test tube of the horseshoe crab reagent sample and no gel is formed in the sample test tube, so the result is negative.
[0037] 2) Serological identification:
[0038] ① Protein determination, total protein BCA test: dilute the protein standard sample in a gradient manner according to the instructions of the BCA protein quantitative test kit, use the blank as the control, and measure it using a spectrophotometer. Calculate the protein content in the sample based on the absorbance value of the sample. According to the total protein content standard curve Y = 0.219X + 0.046 (R2 = 0.996), the average total protein content is 3.13% (W / V).
[0039] ② Hemoglobin determination: the hemoglobin concentration is automatically analyzed by a blood cell analyzer, and a value of ≤20mg / 100ml is considered qualified.
[0040] Example 2: Preparation and identification of umbilical cord blood mesenchymal stem cells
[0041] Take the remaining liquid after removing the plasma in Example 1 and add PBS solution to the original volume, slowly add it to the lymphocyte separation solution, the volume is 1:1, centrifuge (centrifugation parameters: 25°C, 900×g, 20min). After centrifugation, the liquid is divided into 4 layers, from bottom to top, namely, red blood cell layer, separation liquid layer, white film layer, and PBS mixed solution layer. Pipette the white film layer cells, resuspend them with physiological saline, and wash them 3 times. The cells collected in the last time are resuspended and stored in the serum culture medium prepared above, and cultured on the wall to obtain umbilical cord blood mesenchymal stem cells;
[0042] Collecting Umbilical Cord Blood Mesenchymal Stem Cells for Identification:
[0043] ① Flow cytometry identification of stem cell phenotype identification stem cell surface markers CD90, CD105 positive rate ≥ 98%, CD14, CD34, CD45, HLA-DR positive rate ≤ 2%, trypan blue staining to obtain umbilical cord blood mesenchymal stem cells (5 ~ 7.5) × 10 7 indivual.
[0044] ②Morphology: When observed in adherent culture, the cells are spindle-shaped, have good refractive index, and are densely populated and radiate in regular spirals or clusters.
[0045] ③ Differentiation potential detection: identification of osteogenic, chondrogenic and adipogenic differentiation.
[0046] Umbilical cord blood mesenchymal stem cells were collected at 1×10 4 / ml cell concentration was inoculated in a 24-well plate. When the cells reached 70% fusion, the original culture medium was removed and the pre-prepared human umbilical cord mesenchymal stem cell adipogenic, osteogenic and chondrogenic differentiation medium was added. The medium was changed every 3 days for two weeks. When lipid droplets were observed in the cytoplasm of the adipogenic induction group, the culture medium was carefully removed, washed twice with PBS, fixed with 40g / L paraformaldehyde for 20min, and observed and photographed under a microscope after staining with Oil Red O. When round calcified nodules were observed under the microscope in the osteogenic induction group, they were identified by alizarin red staining, and the results of chondrogenic induction were observed under the microscope after staining with toluidine blue.
[0047] After adipogenic induction, the cell morphology gradually changed from a typical long spindle to a shorter, rounder, and oval shape. After 10 days of induction, small dot-like lipid droplets were observed in the cytoplasm under the microscope. After 1 week of induction, the number of lipid droplets in the cytoplasm increased. Oil red O staining showed that a large number of lipid droplets in the cytoplasm were stained red, indicating that umbilical cord blood mesenchymal stem cells have the potential to differentiate into adipocytes in vitro. After about 1 week of osteogenic induction, the cells gradually changed from a long spindle to a square and scaly shape. After 2 weeks of induction, the secretion of extracellular matrix increased, and many small black particles appeared in and outside the cytoplasm. Nodular structures were visible after 3 weeks. Alizarin red staining showed red mineralized deposits. The cartilage differentiation ability was further observed. Toluidine blue staining was used to detect the expression of proteoglycans. Uniform blue staining was observed under the microscope, indicating that umbilical cord blood mesenchymal stem cells have the potential to differentiate into adipogenic, osteogenic, and chondrogenic cells in vitro.
[0048] Example 3: Preparation of biological cell preparations:
[0049] Preparation 1: Umbilical cord blood mesenchymal stem cells, 2.5 ml serum, and 30 mg sodium hyaluronate were mixed, where the concentration of umbilical cord blood mesenchymal stem cells was 1.25×10 7 / mL, the concentration of sodium hyaluronate is 12mg / mL;
[0050] Preparation 2: Add 1g of hyaluronic acid to 250ml of deionized water, stir and dissolve, add 2g of carbodiimide and 1.5g of N-hydroxysuccinimide to dissolve, adjust the pH to 6, stir and react for 30min in the dark, add 2g of L-cysteine hydrochloride to dissolve, adjust the pH to 5, stir and react for 5h in the dark; after the reaction, put it into a dialysis bag, place it in a hydrochloric acid solution with a pH of 5 and a hydrochloric acid solution containing 1wt% sodium chloride at a pH of 5 in turn, dialyze at 21°C in the dark for 4 days, take out and freeze-dry to obtain a freeze-dried sponge solid; take 5mg of freeze-dried sponge solid and add 10ml of deionized water, stir and dissolve, add umbilical cord blood mesenchymal stem cells, 2.5ml of serum, and 30mg of sodium hyaluronate to mix, add 10mg of β-glycerophosphate disodium, dissolve and place in a 37°C water bath to obtain Preparation 2, wherein the number of umbilical cord blood mesenchymal stem cells is 0.25×10 7 Pieces / ml.
[0051] Detection test:
[0052] 1. Establish a rat knee joint injury model. Take 30 rats of the same age and use non-surgical method - joint fixation method: fix the right knee, that is, cause joint stress imbalance and systemic circulation disorder through external pressure, so that the experimental rats will have osteoarthritis-like changes to establish an animal model. Divide them into 3 groups, namely experimental group 1, experimental group 2 and control group.
[0053] Experimental group 1 was injected with 0.1 ml of preparation 1 into the knee joint cavity; experimental group 2 was injected with 0.5 ml of preparation 2 into the knee joint cavity; the control group was injected with 0.1 ml of normal saline into the joint cavity, and the mice were observed on the day of injury, 1 week after treatment, 2 weeks after treatment, and 4 weeks after treatment, which were recorded as W0, W1, W2, and W4 respectively.
[0054] The ZL-024 bipedal balance analgesia meter from Anhui Yaokun Biotechnology Co., Ltd. was used to measure the difference in supporting force between the two hind feet of rats. When the animals are not restrained, there will be a difference in the strength to support body weight between the inflamed and painful foot and the normal foot. The greater the difference, the more painful the inflamed foot is. The bipedal balance analgesia meter can be used to identify the effectiveness of the treatment method.
[0055] The pressure weight values of the left and right feet of rats were collected continuously within 10 seconds. The valid data were collected 3 times for each rat (excluding the data in which the rat's foot was not completely placed on the pressure sensor during the experiment). The difference in weight pressure between the healthy and affected feet was calculated, and the average value was taken as the final result of the ankle pain behavior test for each rat.
[0056] The difference between the two groups was statistically significant (P<0.05).
[0057] Table 1: Measurement results of the bipedal balance analgesia instrument (pressure difference, X±S, g, n=5)
[0058] Time Node Experimental Group 1 Experimental Group 2 Control group W0 24.45±0.76 23.68±0.71 25.51±0.57 W1 7.47±1.32 7.32±1.21 17.38±1.71 W2 0.51±0.23 0.45±0.24 10.37±0.64 W4 0.42±0.21 0.41±0.19 7.56±0.65 P <0.05 <0.05 <0.05
[0059] 2. A total of 140 patients with knee inflammation who were admitted to a provincial tertiary hospital and needed cartilage treatment were screened and divided into two groups. The experimental group had 70 cases, including 34 males and 36 females, aged 45-70 years old with an average age of 52.5 years old; the control group had 70 cases, including 35 males and 35 females, aged 45-70 years old with an average age of 53.1 years old. The medical records of the two groups of patients were basically the same, with no significant differences.
[0060] The experimental group was given intra-articular injection of preparation 1, volume 2.5 ml, once every 2 weeks, for a total of 8 times; the control group was given intra-articular injection of normal saline, volume 2.5 ml, once every 2 weeks, for a total of 8 times. Follow-up was performed 1, 3, 6, and 10 months after injection, and efficacy and safety were evaluated at each visit. Efficacy determination: a total of 4 items. The clinical efficacy of the patient was evaluated according to the patient's clinical symptoms, arthritis and pain severity.
[0061] (1) Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) comprehensive score, a total of 5 items: ① walking on flat ground, ② going up and down stairs, ③ sleeping at night, ④ sitting up or lying down, ⑤ standing, the minimum total score is 0 points, the maximum score is 20 points.
[0062] (2) The Lysholm score evaluates the knee function of meniscus injury based on indicators such as support, locking, pain, swelling, and joint stability.
[0063] (3) Lequesne swelling score: normal (0 points), slight swelling with clear knee joint (1 point), soft tissue swelling with unclear knee joint (2 points), unclear knee joint and floating patella test (+) (3 points).
[0064] Before and after treatment, the scores of the two groups of patients were compared. The scores of the observation group were significantly changed compared with those before treatment, and the difference was statistically significant (P < 0.05); the scores of the control group were not significantly different from those before treatment (P > 0.05). At 6 and 12 months of treatment, the scores of the observation group were significantly better than those of the control group, and the difference was statistically significant (P < 0.05).
[0065] Table 2: Comparison of scores between the two groups of patients ( point)
[0066]
[0067]
[0068] (4) Comparison of knee synovial fluid inflammatory factor levels before and after treatment. Comparison of TNF-α, IL-1β and MMP-13 levels between the two groups showed no significant difference (P>0.05). After treatment, the levels of TNF-α, IL-1β and MMP-13 in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05).
[0069] Table 3: Comparison of the levels of inflammatory factors in knee joint fluid between the two groups of patients ( ng / L )
[0070]
[0071] Observation indicators: The dynamic biomechanics of the lower limbs were accurately measured by the Qualysis three-dimensional motion capture system. The three-dimensional gait analysis system is a method for accurately measuring the dynamic biomechanics of the lower limbs. It collects the gait data of the subjects and calculates the trajectory of joint movement and the force of the joints during the movement. It quantifies the various biomechanical parameters in the gait and indirectly reflects the patient's kinematic and kinetic state. It has the characteristics of simple operation, non-invasiveness and detailed data.
[0072] Before and after treatment, the scores of the two groups of patients were compared. The scores of the observation group were significantly changed compared with those before treatment, and the difference was statistically significant (P < 0.05); there was no statistically significant difference in the scores of the control group compared with those before treatment (P > 0.05).
[0073] Table 4: Comparison of knee joint cadence, step width, step length, step speed and stride length between the two groups of subjects (x±s)
[0074]
[0075] Note: Cadence: Stride frequency; Stride width: Stride width; Step length: Stride length; Walking velocity: Walking speed; Stride length: Stride length
[0076] Conclusion: The above results show that the recovery effect of the experimental group is significantly higher than that of the control group, which indicates that the biological preparation of the present invention can achieve good results in the treatment of knee cartilage injuries and has significant therapeutic effects.
[0077] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art can still modify the technical solutions described in the aforementioned embodiments or replace some of the technical features therein by equivalents. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A biological cell preparation for treating knee joint injury, characterized in that: The biological cell preparation comprises serum, sodium hyaluronate, and umbilical cord blood mesenchymal stem cells, wherein the concentration of umbilical cord blood mesenchymal stem cells is (1-1.5)×10 7 / mL, and the concentration of sodium hyaluronate is 12mg / mL.
2. A biological cell preparation for treating knee joint injury according to claim 1, characterized in that: The biological cell preparation also includes thiolated hyaluronic acid hydrogel.
3. A method for preparing a biological cell preparation for treating knee joint injury, characterized in that: The specific preparation steps are as follows: S1: extracting serum from umbilical cord blood; S2: preparing umbilical cord blood mesenchymal stem cells; S3: adding serum, sodium hyaluronate and umbilical cord blood mesenchymal stem cells to thiolated hyaluronic acid hydrogel to prepare a biological cell preparation.
4. The method for preparing a biological cell preparation for treating knee joint injury according to claim 3, characterized in that: The specific steps of S1 are as follows: Qualified umbilical cord blood was transferred to a centrifuge tube for the first centrifugation, the upper plasma was collected, dihydrated calcium chloride solution was added to the upper plasma to dilute it, the mixture was mixed by inversion, the tube was transferred to a centrifuge tube, and the tube was placed in a water bath at 37°C for 40-50 min. After the plasma coagulated, it was broken and centrifuged for the second time, the upper clarified liquid was collected, frozen at -80°C for 1-2 h, thawed in a water bath at 37°C, and centrifuged for the third time. The supernatant was taken and filtered through a 0.22 μm filter to obtain serum.
5. The method for preparing a biological cell preparation for treating knee joint injury according to claim 3, characterized in that: The specific steps of S2 are as follows: The remaining liquid after removing the plasma was added with PBS phosphate buffer solution, which was slowly added to the lymphocyte separation solution. The layers were centrifuged and separated from each other. From bottom to top, they were: red blood cell layer, separation solution layer, buffy coat layer, and PBS mixed solution layer. The cells in the buffy coat layer were aspirated, resuspended with physiological saline, washed 3 times, resuspended and preserved with serum prepared by S1, and cultured adherently to obtain umbilical cord blood mesenchymal stem cells.
6. The method for preparing a biological cell preparation for treating knee joint injury according to claim 4, characterized in that: The concentration of calcium chloride dihydrate is 1 mol / L, and it is diluted to Ca 2+ The final concentration is 15-20mmol / L.
7. The method for preparing a biological cell preparation for treating knee joint injury according to claim 4, characterized in that: The first centrifugation parameters in S1 were set as: 700×g at 4°C for 10 min; the second centrifugation parameters were set as: 2000×g at 4°C for 5 min; the third centrifugation parameters were set as: 750×g at 4°C for 10 min.
8. The method for preparing a biological cell preparation for treating knee joint injury according to claim 5, characterized in that: The centrifugation parameters were set at 900 × g for 20 min at 25 °C.
9. According to the method for preparing a biological cell preparation for treating knee joint injury of claim 3, the specific steps of S3 are as follows: Add hyaluronic acid to deionized water, stir and dissolve, add carbodiimide and N-hydroxysuccinimide to dissolve, adjust the pH to 5-6, stir and react for 30 minutes in the dark, add L-cysteine hydrochloride to dissolve, adjust the pH to 5-6, stir and react for 5 hours in the dark; after the reaction, put it into a dialysis bag for dialysis, freeze-dry to obtain a freeze-dried sponge solid, add deionized water, stir and dissolve, add umbilical cord blood mesenchymal stem cells, serum, and sodium hyaluronate to mix; then add β-disodium glycerophosphate, dissolve and place in a 37°C water bath to obtain a biological cell preparation.
10. The method for preparing a biological cell preparation for treating knee joint injury according to claim 9, characterized in that: The specific steps of dialysis are: the dialysis bag is placed in a hydrochloric acid solution with a pH of 5 and a hydrochloric acid solution with a pH of 5 containing 1 wt% sodium chloride in sequence, and the dialysis is performed at 21° C. in the dark for 4 to 6 days.
